COMPASS Pathways

British science is often held up as a shining light: both a source of national pride thanks to the country’s huge contributions in the past, and a crucial part of the economy which should help drive g

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a

Advocates for psychedelics have cast a concerned glance at the news that the leader in the field, Compass Pathways, has again pushed back pivotal data readouts for its treatment-resistant depression (

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals